 |
AMERICAN FORK, Utah, June 20, 2023 /PRNewswire/ -- IBC Advanced Technologies, Inc. ("IBC") announces the launch of a full range of tools for theranostics utilizing proprietary Molecular Recognition Technology™ (MRT™.)
Flowsheets based on highly selective MRT™ products and processes utilize IBC's proprietary molecules tailored to target specific ions in terms of matching their shapes and coordination chemistry. These molecules are attached to support materials such as organic polymers or silicates to create reusable MRT™ resins that bind target radionuclides with exceptionally high selectivity in packed column mode. The bound target radionuclide is removed by elution with very high rates of purity and recovery, up to 99.99% pure and 99.9+% yield, using chemically simple solutions.
Highly selective MRT™ materials have been cited as green chemistry reagents [1] for the following reasons:
MRT™ products have found uses [2] in highly selective recovery of valuable materials, waste treatment, chemical analysis and many other applications including individual radionuclide separations and high recovery at high purity.
Properties of MRT™ flowsheets that make them useful for separations in the medical radioisotope field are:
IBC has many highly selective MRT™ separation systems available and in use in radioisotope as well as non-radioisotope applications across the periodic table. IBC works closely with each customer to design, build, and commission a customized separation system to meet their needs.
IBC also manufactures individual chelating agents and other ligands to complex metal ions independently or to conjugate radioisotopes to vector molecules, including small molecules, peptides and monoclonal antibodies.
IBC's proprietary flowsheets offer high purity, high recovery rate processes for radioisotopes that have the added advantage of simplified, usually single step, recovery with minimal generation of waste from the process. IBC believes these properties offer economic advantages for individual isotope production and for recovering expensive (enriched) target materials that can be applied to established and developing processes in the nuclear field.
Dr. Robert G. G. Holmes, former Chief Scientist at Canadian Nuclear Labs, commented, "There is a resurgence of interest in radiopharmaceuticals, particularly the targeted therapies using Lu-177, Ac-225, Ra-223and Pb-212. MRT™ has been extensively proven on key radioisotopes both in and outside the radiopharmaceutical industry. MRT™ provides many advantages and benefits in the recovery of radioisotopes and other valuable target materials, exploiting the key properties of high selectivity and high recovery rates which result in waste minimization, process simplification, enhanced recovery and associated cost savings."
Steven R. Izatt, President and CEO of IBC, commented, "With this launch, IBC is providing the radiopharmaceutical industry with the key tools it needs to industrially produce pure radionuclides for radiopharmaceuticals while minimizing waste, substantially reducing production time and dramatically increasing output. MRT™ is used worldwide for the green production and chelation of metals. We have harnessed this industrial expertise to revolutionize industrial production of pure radioisotopes and chelating agents."
Background of IBC
IBC is an award-winning manufacturer and supplier of highly selective separations products, engineered systems and processes based on Molecular Recognition Technology™ (MRT™.) Based on green chemistry and green engineering principles, IBC's MRT™ products and associated processes are used worldwide in medical, mining, metals, manufacturing, environmental, analytical and laboratory applications.
References
CONTACT: Steven R. Izatt, sizatt@ibcmrt.com, www.ibcmrt.com
